Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP)
Status:
Enrolling by invitation
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
3-part study of patients with psoriasis, including 1) a population based questionnaire 2)
cross-sectional clinical study with focus on musculoskeletal ultrasound and patient reported
outcomes 3) 12 months follow-up study of patients with certain ultrasonic signs of psoriatic
arthritis. Patients with pain: Interventional with 6 months treatment with apremilast,
followed by 6 months observation. Patients without pain: 12 months observation.
Phase:
Phase 4
Details
Lead Sponsor:
Professor Mikkel Østergaard
Collaborators:
Celgene Corporation The Danish Psoriasis Association The Danish Rheumatism Association